Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

被引：127

作者：

Lyke, Kirsten E. ^{[1
]}

Atmar, Robert L. ^{[2
]}

Islas, Clara Dominguez ^{[3
]}

Posavad, Christine M. ^{[3
,4
]}

Szydlo, Daniel ^{[5
]}

Chourdhury, Rahul Paul ^{[5
]}

Deming, Meagan E. ^{[1
]}

Eaton, Amanda ^{[6
]}

Jackson, Lisa A. ^{[7
]}

Branche, Angela R. ^{[8
]}

Sahly, Hana M. El ^{[2
]}

Rostad, Christina A. ^{[9
]}

Martin, Judith M. ^{[10
]}

Johnston, Christine ^{[3
,4
,11
]}

Rupp, Richard E. ^{[12
]}

Mulligan, Mark J. ^{[13
]}

Brady, Rebecca C. ^{[14
]}

Frenck, Robert W., Jr. ^{[14
]}

Backer, Martin ^{[15
]}

Kottkamp, Angelica C. ^{[13
]}

Babu, Tara M. ^{[11
]}

Rajakumar, Kumaravel ^{[10
]}

Edupuganti, Srilatha ^{[16
,17
]}

Dobrzynski, David ^{[8
]}

Coler, Rhea N. ^{[18
,19
]}

Archer, Janet I. ^{[20
]}

Crandon, Sonja ^{[21
]}

Zemanek, Jillian A. ^{[5
]}

Brown, Elizabeth R. ^{[3
]}

Neuzil, Kathleen M. ^{[1
]}

Stephens, David S. ^{[16
]}

Post, Diane J. ^{[21
]}

Nayak, Seema U. ^{[21
]}

Suthar, Mehul S. ^{[22
]}

Roberts, Paul C. ^{[21
]}

Beigel, John H. ^{[21
]}

Montefiori, David C. ^{[23
]}

DMID Std Grp

机构：

[1] Univ Maryland Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA

[2] Baylor Coll Med, Dept Med & Mol Virol & Microbiol, Houston, TX 77030 USA

[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA USA

[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Lab Med & Pathol, Seattle, WA USA

[5] Univ Washington, Stat Ctr HIV AIDS Res & Prevent SCHARP, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Duke Univ Med Ctr, Dept Surg, Durham, NC USA

[7] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA

[8] Univ Rochester, Dept Med, Div Infect Dis, Rochester, NY USA

[9] Emory Univ Sch Med & Childrens Healthcare Atlanta, Ctr Childhood Infect & Vaccines, Dept Pediat, Atlanta, GA USA

[10] Univ Pittsburgh Sch Med, Dept Pediat, Pittsburgh, PA USA

[11] Univ Washington, Dept Med, Seattle, WA USA

[12] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX USA

[13] NYU Langone Vaccine Ctr, NYU Grossman Sch Med, Dept Med, Div Infect Dis & Immunol, New York, NY USA

[14] Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH USA

[15] NYU Langone Hosp, Mineola, NY USA

[16] Emory Univ Sch Med, Dept Med, Atlanta, GA USA

[17] Hope Clin Emory Vaccine Ctr, Atlanta, GA USA

[18] Univ Washington Sch Med, Seattle Childrens Res Inst, Seattle, WA USA

[19] Univ Washington Sch Med, Dept Pediat, Seattle, WA USA

[20] FHI360, Durham, NC 27701 USA

[21] Natl Inst Allergy & Infect Dis, NIH, Div Microbiol & Infect Dis, Bethesda, MD USA

[22] Emory Univ, Atlanta, GA USA

[23] Duke Univ Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 07期

基金：

美国国家卫生研究院;

关键词：

BA.2.12.1; BA.4/BA.5; booster; COVID-19; mRNA vaccine; neutralizing antibody; Omicron variant; recombinant adenovirus vaccine; SARS-CoV-2; sublineage;

D O I：

10.1016/j.xcrm.2022.100679

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to generate protective immunity. We assess the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. All prime-boost combinations substantially increase the neutralization titers to Omicron, although the boosted titers decline rapidly within 2 months from the peak response compared with boosted titers against the prototypic D614G variant. Boosted Omicron neutralization titers are substantially higher for homologous mRNA vaccine boosting, and for heterologous mRNA and Ad26.COV2.S vaccine boosting, compared with homologous Ad26.COV2.S boosting. Homologous mRNA vaccine boosting generates nearly equivalent neutralizing activity against Omicron sublineages BA.1, BA.2, and BA.3 but modestly reduced neutralizing activity against BA.2.12.1 and BA.4/BA.5 compared with BA.1. These results have implications for boosting requirements to protect against Omicron and future variants of SARS-CoV-2.

引用

页数：13

共 50 条

[21] SARS-CoV-2 Omicron variant: Immune escape and vaccine development
Ao, Danyi
Lan, Tianxia
He, Xuemei
Liu, Jian
Chen, Li
Baptista-Hon, Daniel T.
Zhang, Kang
Wei, Xiawei
MEDCOMM, 2022, 3 (01):
[22] SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection
Baerends, Eva A. M.
Hvidt, Astrid K.
Reekie, Joanne
Sogaard, Ole S.
Staerke, Nina B.
Raben, Dorthe
Nielsen, Henrik
Petersen, Kristine T.
Juhl, Maria R.
Johansen, Isik S.
Lindvig, Susan O.
Madsen, Lone W.
Wiese, Lothar
Knudsen, Lene S.
Iversen, Mette B.
Benfield, Thomas
Iversen, Kasper K.
Andersen, Sidsel D.
Juhl, Anna K.
Dietz, Lisa L.
Andreasen, Signe R.
Fischer, Thea K.
Erikstrup, Christian
Valentiner-Branth, Palle
Lundgren, Jens
Ostergaard, Lars
Tolstrup, Martin
ISCIENCE, 2023, 26 (09)
[23] A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
Lam, Joy-Yan
Ng, Yau-Yee
Yuen, Chun-Kit
Wong, Wan-Man
Yuen, Kwok-Yung
Kok, Kin-Hang
EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 964 - 967
[24] Airborne Transmission of the SARS-CoV-2 Delta Variant and the SARS-CoV-2 Omicron Variant
Lee, Byung Uk
AEROSOL AND AIR QUALITY RESEARCH, 2022, 22 (01)
[25] Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies
Shen, Kuan-Yin
Yang, Chung-Hsiang
Chen, Chiung-Tong
Ho, Hui-Min
Chiu, Fang-Feng
Huang, Chiung-Yi
Liao, Hung-Chun
Hsu, Chia-Wei
Yu, Guann-Yi
Liao, Ching-Len
Chen, Hsin-Wei
Huang, Ming-Hsi
Liu, Shih-Jen
JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
[26] A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
I-Jung Lee
Cheng-Pu Sun
Ping-Yi Wu
Yu-Hua Lan
I-Hsuan Wang
Wen-Chun Liu
Joyce Pei-Yi Yuan
Yu-Wei Chang
Sheng-Che Tseng
Szu-I Tsung
Yu-Chi Chou
Monika Kumari
Yin-Shiou Lin
Hui-Feng Chen
Tsung-Yen Chen
Chih-Chao Lin
Chi-Wen Chiu
Chung-Hsuan Hsieh
Cheng-Ying Chuang
Chao-Min Cheng
Hsiu-Ting Lin
Wan-Yu Chen
Fu-Fei Hsu
Ming-Hsiang Hong
Chun-Che Liao
Chih-Shin Chang
Jian-Jong Liang
Hsiu-Hua Ma
Ming-Tsai Chiang
Hsin-Ni Liao
Hui-Ying Ko
Liang-Yu Chen
Yi-An Ko
Pei-Yu Yu
Tzu-Jing Yang
Po-Cheng Chiang
Shang-Te Hsu
Yi-Ling Lin
Chong-Chou Lee
Han-Chung Wu
Mi-Hua Tao
Journal of Biomedical Science, 29
[27] Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies
Schulz, Sebastian R.
Hoffmann, Markus
Roth, Edith
Pracht, Katharina
Burnett, Deborah L.
Mazigi, Ohan
Schuh, Wolfgang
Manger, Bernhard
Mielenz, Dirk
Goodnow, Christopher C.
Christ, Daniel
Poehlmann, Stefan
Jaeck, Hans-Martin
EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 (06) : 970 - 977
[28] Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant
Del Mastro, Andrea
Picascia, Stefania
D'Apice, Luciana
Trovato, Maria
Barba, Pasquale
Di Biase, Immacolata
Di Biase, Sebastiano
Laccetti, Marco
Belli, Antonello
Amato, Gerardino
Di Muro, Potito
Credendino, Olga
Picardi, Alessandra
De Berardinis, Piergiuseppe
Del Pozzo, Giovanna
Gianfrani, Carmen
VIRUSES-BASEL, 2023, 15 (05):
[29] Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
Zhou, Guangyu
Zhao, Qi
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (10): : 1718 - 1723
[30] Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2
Chen, Chunxia
Liang, Jiahui
Hu, Hangzhan
Li, Xiaoquan
Wang, Li
Wang, Zhizeng
ANALYTICAL BIOCHEMISTRY, 2023, 673

← 1 2 3 4 5 →